How do I exclude thrombotic microangiopathy (TMA) in a patient presenting with anemia, thrombocytopenia, and possible organ dysfunction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Exclude Thrombotic Microangiopathy (TMA)

To exclude TMA, you must demonstrate the absence of both microangiopathic hemolytic anemia (MAHA) and thrombocytopenia through specific laboratory findings: normal platelet count, absence of schistocytes on blood film, normal LDH, detectable haptoglobin, and normal reticulocyte count. 1, 2

Initial Laboratory Screening

When TMA is suspected, immediately order:

Essential Tests to Exclude TMA:

  • Complete blood count with platelet count - TMA typically shows platelets <30 × 10⁹/L, though higher counts don't exclude it 1, 2
  • Blood film examination within 60 minutes - Look for schistocytes (red cell fragments), though these may be initially absent in up to some cases 1
  • Reticulocyte count - Elevated (>120 × 10⁹/L) suggests hemolysis; low reticulocyte production index argues against TMA and toward pseudo-TMA 1, 3
  • Serum haptoglobin - Undetectable in hemolysis; detectable levels help exclude TMA 1
  • Lactate dehydrogenase (LDH) - Elevated in hemolysis; levels >2500 units/L suggest pseudo-TMA from B12 deficiency rather than true TMA 3
  • Coagulation profile (PT/PTT, fibrinogen) - Normal in TMA; abnormal suggests DIC instead 1
  • Direct antiglobulin test (DAT/Coombs) - Nearly always negative in TTP; positive suggests autoimmune hemolytic anemia 2

Critical Differentiating Features

If TMA is Present, Determine the Type:

Immediately send ADAMTS13 activity before any plasma therapy 2:

  • ADAMTS13 <10% = TTP (97% sensitivity, 100% specificity) 2
  • ADAMTS13 >10% = Other TMA (complement-mediated, HUS, secondary causes) 4

Key Clinical Clues That Help Exclude Specific TMAs:

Severe renal dysfunction (creatinine >2.0-2.25 mg/dL):

  • Argues against TTP and toward HUS or complement-mediated TMA 2
  • TTP typically shows mild-to-moderate kidney dysfunction 2

Normal coagulation parameters:

  • Excludes DIC as the cause 1

Pancytopenia with low reticulocyte production index:

  • Suggests pseudo-TMA from B12 deficiency, not true TMA 3

Absence of neurologic, cardiac, or renal involvement:

  • Makes TMA less likely but doesn't exclude it, as 18% of TTP patients are ambulatory at diagnosis 2

Common Pitfalls to Avoid

  1. Don't wait for schistocytes - They may be absent initially or missed on routine review 1

  2. Don't rely solely on platelet count - Platelets ≥30 × 10⁹/L don't exclude TMA, though they make other diagnoses more likely 2

  3. Don't assume normal ADAMTS13 excludes all TMA - It only excludes TTP; other TMAs (complement-mediated, HUS, secondary) will have ADAMTS13 >10% 4, 5

  4. Don't miss renal-limited TMA - Can occur without systemic hematologic abnormalities; requires kidney biopsy for diagnosis 6

  5. Don't forget pseudo-TMA from B12 deficiency - Check B12 level if LDH is exaggeratedly elevated (>2500), patient appears clinically well, and has pancytopenia with low reticulocyte count 3

Algorithmic Approach to Exclusion

Step 1: Check CBC with platelets

  • Normal platelets → TMA unlikely (but check blood film anyway if anemia present)

Step 2: Examine blood film urgently

  • No schistocytes + normal platelets + normal LDH + detectable haptoglobin → TMA excluded

Step 3: If thrombocytopenia and/or hemolysis present:

  • Check coagulation profile → abnormal = DIC, not primary TMA
  • Check DAT → positive = consider autoimmune hemolytic anemia
  • Check pregnancy test in women
  • Check B12 level if LDH >2500 and patient appears well

Step 4: If MAHA + thrombocytopenia confirmed:

  • Send ADAMTS13 activity (before plasma therapy) 1
  • Assess organ involvement (troponin, creatinine, neurologic exam) 2
  • Consider kidney biopsy if no systemic features but AKI present 6

Step 5: Interpret ADAMTS13:

  • <10% = TTP confirmed
  • 10% = Consider complement-mediated TMA, HUS, or secondary causes 4

The most recent guidelines emphasize that laboratories must have documented rapid pathways for blood film examination within 60 minutes when platelets are <30 × 10⁹/L, with immediate escalation to clinical hematology if hemolysis is present 1. Access to urgent ADAMTS13 testing (turnaround 30-40 minutes with automated assays) is now standard of care 1.

Related Questions

What is the appropriate diagnosis and management of thrombotic microangiopathy (TMA)?
What are the imaging findings of renal thrombotic microangiopathy (TMA)?
What is the urgent management for a patient presenting with mild anemia, microcytosis, low RBC count, severe thrombocytopenia, hyperbilirubinemia, and markedly elevated LDH consistent with a hemolytic microangiopathy?
How should I evaluate and manage a patient with suspected complement‑mediated thrombotic microangiopathy presenting with recurrent hemoglobinuria, stage III hypertension, proteinuria, oliguria, Raynaud phenomenon, pressure petechiae, intermittent platelet count drops of approximately 30 % with concurrent red‑cell mass loss, transient neurologic (TIA‑like) events, paroxysmal atrial fibrillation, gastrointestinal ischemia‑like symptoms, and a modestly low Factor D level?
What are the likely differential diagnoses for a patient with acute kidney injury and stroke whose renal biopsy shows microangiopathy?
In an adult with hyperacidity, can butamirate be used and what is the appropriate dose?
How can I become an effective, compassionate physician?
How can I become more informed about medical diagnosis and treatment?
How should sertraline (Serdep) and escitalopram (Lexamil) be used as first‑line therapy for anxiety disorders?
What are the structural differences between sertraline (Serdep) and escitalopram (Lexamil)?
What infusion rate can be used for D5NS (5% dextrose in normal saline) containing 20 mEq potassium chloride?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.